abstract |
This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition comprising an immunoadjuvant compound, wherein said immunoadjuvant compound consists of a Rho GTPase activator. |